No Data
No Data
No Data
No Data
No Data
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a
GlobeNewswireMay 3 05:13
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel monoclonal antibodiesCompany now expects to end 2024 with at
GlobeNewswireApr 30 19:30
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes From the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA
Product-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224) defines reimbursement for product administrationReimbursement through Medicare/Medicaid represents
GlobeNewswireApr 15 19:30
Invivyd Reveals CEO Transition; Appoints Jeremy Gowler As Interim CEO, Effective Immediately, To Succeed Dave Hering
Invivyd Reveals CEO Transition; Appoints Jeremy Gowler As Interim CEO, Effective Immediately, To Succeed Dave Hering
BenzingaApr 12 19:33
Invivyd: Gowler Succeeds Dave Hering in the Role>IVVD
Invivyd: Gowler Succeeds Dave Hering in the Role>IVVD
Dow JonesApr 12 19:31
Press Release: Invivyd Announces CEO Transition
Invivyd Announces CEO Transition Jeremy Gowler appointed Interim CEO WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to prot
Dow JonesApr 12 19:30
No Data
No Data